Loading the session
Loading the session
Loading instrument
$8.62
+0.35%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:20 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −25.6% (SPY −1.6%, XLV +13.5%). 3 months: −36.7% (SPY −0.4%, XLV +15.5%). 1 year: +29.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CMPS, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 close of $8.60 was 31.6% below its 50-day average ($12.57) and 17.5% below its 200-day average ($10.42). It has closed below the 200-day for 3 sessions, since 2 Nov 2026. The 50-day average crossed above the 200-day on 3 Sep 2025, 295 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
17.7M shares were sold short at the 15 Oct 2026 settlement, 12.8% of the 138.5M shares outstanding; covering them would take 6.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 14-session relative strength index closed at 29.8 on 4 Nov 2026, its 3rd session at 30 or below. By convention a reading of 30 or below is called oversold and 70 or above overbought.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Closed at $8.60 on 4 Nov 2026: 45.8% below the 52-week high of $15.87 (9 Sep 2026) and 76.2% above the low of $4.88 (24 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
April 20, 2026
+42.04%February 17, 2026
+31.33%June 23, 2025
−49.24%